Pricing Log in Create free account

Recursion Pharmaceuticals, Inc. (RXRX) vs Zai Lab Limited Unsponsored ADR (ZLAB)

Recursion Pharmaceuticals, Inc. and Zai Lab Limited Unsponsored ADR are both Biotechnology companies. Zai Lab Limited Unsponsored ADR is the larger, with a market value of $2.6B against $2.2B — 1.2× the size. Recursion Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 56.2% against 0.02%. Zai Lab Limited Unsponsored ADR has the higher net margin (−44.9% vs −697.1%) and the higher return on invested capital (−21.3% vs −88.5%). Across the 18 metrics below, Zai Lab Limited Unsponsored ADR leads on 11 and Recursion Pharmaceuticals, Inc. on 7.

Valuation

Metric RXRX ZLAB Biotechnology median
P/E n/m n/m 10.26
P/S 27.93 5.74 9.18
P/B 2.10 4.50 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 19.78 4.68 8.98
Earnings yield (25.62%) (7.54%) (34.89%)
Free cash flow yield (16.50%) (7.77%) (24.52%)

Profitability

Metric RXRX ZLAB Biotechnology median
Gross margin 29.21% 0.00% 65.16%
Operating margin (725.44%) (62.99%) 0.00%
Net margin (697.13%) (44.91%) 0.00%
Free cash flow margin (460.89%) (44.57%) 0.00%
Return on equity (48.72%) (29.99%) (50.12%)
Return on assets (36.29%) (18.18%) (45.60%)
Return on invested capital (88.54%) (21.32%) 0.00%

Growth

Metric RXRX ZLAB Biotechnology median
Revenue growth (TTM) 56.18% 0.02% 6.26%
EPS growth (last fiscal year) 14.79% 38.46% 29.88%
Revenue growth, 5-year CAGR 79.91% 56.54% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric RXRX ZLAB Biotechnology median
Debt to equity 0.00 0.45 0.00
Current ratio 5.01 2.04 4.89
Net debt to EBITDA 1.31 2.66 1.01

Dividend

Metric RXRX ZLAB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric RXRX ZLAB Biotechnology median
Market cap 2.18b 2.55b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack